It remains to be determined whether the absence of PDE4C activity in skeletal muscle using PDE4C inhibitors can promote an increased muscle mass in the absence of an identifiable muscle disease or improve muscle atrophy in clinical neuropathies and myopathies. The gene discussed is PDE4C; the disease is neuropathy.